Thai, U.S. Trade Meeting Set Over Compulsory License Policy
This article was originally published in PharmAsia News
Thailand's Commerce Ministry permanent secretary scheduled a meeting with a U.S. Trade Representative official March 17 on the Asian nation's compulsory licensing policy on drug patents. The United States is to decide by the end of April whether to take Thailand off its Priority Watch List for countries that violate global intellectual property protection rules. Thai Commerce Minister Mingkwan Sangsuwan also is set to meet with USTR head Susan Schwab next month in Bangkok. Several Thai ministries are to decide this week on the status of the CL policy. (Click here for more
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.